Abcam, ab317616, Anti-ST8SiaIII antibody [EPR28521-92]

Size: 10µL-TRIAL / 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal ST8SiaIII antibody. Suitable for I-ELISA, ICC/IF, WB, IP, IHC-Fr, IHC-P and reacts with Recombinant fragment - Human, Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28521-92,
Isotype:IgG,
Carrier free:No,
Reacts with:Human, Mouse, Rat,
Applications:IHC-P, IP, I-ELISA, ICC/IF, IHC-Fr, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Unsuitable for rat WB.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ST8SiaIII also known as Sialyltransferase 8B is an enzyme weighing approximately 43 kDa. This enzyme plays a mechanical role in the brain where it contributes to the synthesis of polysialic acid chains. ST8SiaIII adds sialic acid residues to glycoproteins and glycolipids catalyzing the transfer of these residues to terminal ends of N-glycans on proteins notably NCAM1 (Neural Cell Adhesion Molecule 1). The enzyme is expressed in the nervous system specifically detected in the brain tissue where it influences neural activity and development.
Biological function summary
ST8SiaIII modifies neural cell surfaces impacting cell-cell interactions and neural plasticity. It does not operate as a singular entity and is often part of larger glycosylation complexes working in tandem with other sialyltransferases such as ST8SiaII. Through these modifications it regulates the extent of polysialylation which is necessary for processes like cell migration synaptic plasticity and axonal growth. Therefore ST8SiaIII plays a pivotal role in neural development and the central nervous system's adaptability.
Pathways
Polysialylation mediated by ST8SiaIII fits within critical signal transduction pathways like the neural development pathway. This pathway entails multiple proteins where ST8SiaIII interacts particularly with NCAM1 facilitating neuronal changes and synapse formation. It is also part of broader glycosylation pathways contributing to cellular communication and signal transduction. Through these pathways the enzyme influences neural connectivity and cognitive functions forming a network with similar glyco-enzyme participants.
ST8SiaIII has associations with neurological conditions such as schizophrenia and Alzheimer’s disease. Changes in polysialic acid expression levels can disrupt neural functions influencing disease progression. These changes affect linked proteins including NCAM1 highlighting the enzyme's role in neural health. Misregulation of ST8SiaIII activity could lead to altered synapse formation and stability therefore contributing to cognitive deficits seen in these disorders. Understanding its function and regulation may provide insights into disease mechanisms and potential therapeutic avenues.